Immune checkpoint inhibitors can significantly improve cancer survival rates. But resulting immune-related toxicities are common, requiring multidisciplinary cooperation between oncology and neurology. This episode, PN's podcast editor Dr. Amy Ross Russell speaks with a panel of experts on the balancing act required when treating cancer patients with these new drugs. Oncologist Dr. Heather Shaw¹ is alongside neurologists Dr. Aisling Carr² and Dr. Mark Willis³, and they are amongst the authors of the editors' choice paper for the latest issue of Practical Neurology. Read the paper: Neurological complications of immune checkpoint inhibitors: a practical guide (1) Department of Oncology, University College London Hospitals NHS Foundation Trust, London, London, UK (2) Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK (3) Department of Neurology, University Hospital of Wales, Cardiff, UK Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. Production by Letícia Amorim, Brian Kennedy, Amy Ross Russell and Brian O'Toole. Editing by Brian O'Toole. Thank you for listening.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related